{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T04:15:41Z","timestamp":1778991341338,"version":"3.51.4"},"reference-count":98,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000072","name":"National Institute of Dental and Craniofacial Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000072","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.bone.2019.115141","type":"journal-article","created":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T11:52:35Z","timestamp":1573127555000},"page":"115141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Anti-vascular endothelial growth factor antibody monotherapy causes destructive advanced periodontitis in rice rats (Oryzomys palustris)"],"prefix":"10.1016","volume":"130","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2261-3380","authenticated-orcid":false,"given":"J.G.","family":"Messer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.J.","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.M.","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.","family":"Jiron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Israel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.F.","family":"Yarrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.C.","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.D.","family":"Wnek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Jorgensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Wanionok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Van Poznak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Bhattacharyya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.B.","family":"Kimmel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8100-5839","authenticated-orcid":false,"given":"J.I.","family":"Aguirre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.bone.2019.115141_bb0005","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J. Bone Miner. Res."},{"issue":"22","key":"10.1016\/j.bone.2019.115141_bb0010","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1056\/NEJMp068157","article-title":"Osteonecrosis of the jaw\u2014do bisphosphonates pose a risk?","volume":"355","author":"Bilezikian","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.bone.2019.115141_bb0015","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J. Oral Maxillofac. Surg."},{"issue":"1","key":"10.1016\/j.bone.2019.115141_bb0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J. Bone Miner. Res."},{"issue":"35","key":"10.1016\/j.bone.2019.115141_bb0025","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.bone.2019.115141_bb0030","first-page":"2035","article-title":"RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): non bis in idem?","volume":"19","author":"Van den Wyngaert","year":"2011","journal-title":"Support Care Cancer"},{"issue":"12","key":"10.1016\/j.bone.2019.115141_bb0035","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1093\/annonc\/mdn653","article-title":"Bevacizumab-associated osteonecrosis of the jaw","volume":"19","author":"Greuter","year":"2008","journal-title":"Ann. Oncol."},{"issue":"24","key":"10.1016\/j.bone.2019.115141_bb0040","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1200\/JCO.2007.15.5424","article-title":"Osteonecrosis of the jaw related to bevacizumab","volume":"26","author":"Estilo","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bone.2019.115141_bb0045","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.oraloncology.2011.07.030","article-title":"A case report of bevacizumab-related osteonecrosis of the jaw: old problem, new culprit","volume":"48","author":"Disel","year":"2012","journal-title":"Oral Oncol."},{"issue":"6","key":"10.1016\/j.bone.2019.115141_bb0050","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.arbres.2012.01.007","article-title":"Osteonecrosis of the jaw in a patient with advanced non-small-cell lung cancer receiving bevacizumab","volume":"48","author":"Katsenos","year":"2012","journal-title":"Arch. Bronconeumol."},{"issue":"4","key":"10.1016\/j.bone.2019.115141_bb0055","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1177\/039463200902200429","article-title":"Bevacizumab-related osteneocrosis of the jaw","volume":"22","author":"Serra","year":"2009","journal-title":"Int. J. Immunopathol. Pharmacol."},{"issue":"2","key":"10.1016\/j.bone.2019.115141_bb0060","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/07357900802208608","article-title":"Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents","volume":"27","author":"Aragon-Ching","year":"2009","journal-title":"Cancer Investig."},{"issue":"1","key":"10.1016\/j.bone.2019.115141_bb0065","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10549-010-0866-3","article-title":"Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer","volume":"122","author":"Guarneri","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"issue":"10","key":"10.1016\/j.bone.2019.115141_bb0070","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw\u20142014 update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J. Oral Maxillofac. Surg."},{"issue":"2","key":"10.1016\/j.bone.2019.115141_bb0075","first-page":"383","article-title":"Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review","volume":"27","author":"Nicolatou-Galitis","year":"2019","journal-title":"Support Care Cancer"},{"issue":"4","key":"10.1016\/j.bone.2019.115141_bb0080","article-title":"Prevalence of medication-related osteonecrosis of the jaw in patients with breast cancer, prostate cancer, and multiple myeloma","volume":"4","author":"Rugani","year":"2016","journal-title":"Dent J (Basel)"},{"issue":"5","key":"10.1016\/j.bone.2019.115141_bb0085","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ijom.2015.01.026","article-title":"Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review","volume":"44","author":"Fliefel","year":"2015","journal-title":"Int. J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.bone.2019.115141_bb0090","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.bone.2013.10.002","article-title":"Clinical study evaluating the effect of bevacizumab on the severity of zoledronic acid-related osteonecrosis of the jaw in cancer patients","volume":"58","author":"Lescaille","year":"2014","journal-title":"Bone"},{"issue":"4","key":"10.1016\/j.bone.2019.115141_bb0095","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.clbc.2011.02.001","article-title":"Osteonecrosis of the jaw: dental outcomes in metastatic breast cancer patients treated with bisphosphonates with\/without bevacizumab","volume":"11","author":"Ngamphaiboon","year":"2011","journal-title":"Clin Breast Cancer"},{"issue":"3","key":"10.1016\/j.bone.2019.115141_bb0100","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000201931","article-title":"Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone","volume":"76","author":"Christodoulou","year":"2009","journal-title":"Oncology"},{"issue":"6","key":"10.1016\/j.bone.2019.115141_bb0105","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.2005.04.2465","article-title":"Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors","volume":"24","author":"Badros","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bone.2019.115141_bb0110","first-page":"8","article-title":"Antiresorptive treatment-associated ONJ","volume":"20","author":"Eleutherakis-Papaiakovou","year":"2017","journal-title":"Euro. J. Cancer Care"},{"issue":"2","key":"10.1016\/j.bone.2019.115141_bb0115","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.coms.2014.01.005","article-title":"Anti-resorptive osteonecrosis of the jaws: facts forgotten, questions answered, lessons learned","volume":"26","author":"Carlson","year":"2014","journal-title":"Oral. Maxillofac. Surg. Clin. North Am"},{"issue":"11","key":"10.1016\/j.bone.2019.115141_bb0120","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.joms.2005.07.010","article-title":"Bisphosphonate-induced exposed bone (osteonecrosis\/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment","volume":"63","author":"Marx","year":"2005","journal-title":"J. Oral Maxillofac. Surg."},{"issue":"8","key":"10.1016\/j.bone.2019.115141_bb0125","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1002\/jbmr.379","article-title":"Periodontal disease and bisphosphonates induce osteonecrosis of the jaws in the rat","volume":"26","author":"Aghaloo","year":"2011","journal-title":"J. Bone Miner. Res."},{"issue":"10","key":"10.1016\/j.bone.2019.115141_bb0130","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1002\/jbmr.1669","article-title":"Oncologic doses of zoledronic acid induce osteonecrosis of the jaw-like lesions in rice rats (Oryzomys palustris) with periodontitis","volume":"27","author":"Aguirre","year":"2012","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bone.2019.115141_bb0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/clr.12502","article-title":"Role of periodontal disease in bisphosphonate-related osteonecrosis of the jaws in ovariectomized rats","volume":"27","author":"Li","year":"2016","journal-title":"Clin. Oral Implants Res."},{"issue":"11","key":"10.1016\/j.bone.2019.115141_bb0140","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/j.joen.2016.07.020","article-title":"Preexisting periapical inflammatory condition exacerbates tooth extraction-induced bisphosphonate-related osteonecrosis of the jaw lesions in mice","volume":"42","author":"Song","year":"2016","journal-title":"J. Endod"},{"issue":"1","key":"10.1016\/j.bone.2019.115141_bb0145","first-page":"43","article-title":"Prevalence of food impaction-induced periodontitis in conventionally housed marsh rice rats (Oryzomys palustris)","volume":"67","author":"Messer","year":"2017","journal-title":"Comp Med"},{"issue":"7","key":"10.1016\/j.bone.2019.115141_bb0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201343","article-title":"Factors affecting development of medication-related osteonecrosis of the jaw in cancer patients receiving high-dose bisphosphonate or denosumab therapy: is tooth extraction a risk factor?","volume":"13","author":"Soutome","year":"2018","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.bone.2019.115141_bb0155","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/adj.12217","article-title":"Denosumab and osteonecrosis of the jaws - the pharmacology, pathogenesis and a report of two cases","volume":"59","author":"O'Halloran","year":"2014","journal-title":"Aust. Dent. J."},{"issue":"9","key":"10.1016\/j.bone.2019.115141_bb0160","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.jcms.2018.05.046","article-title":"Osteonecrosis of the jaw in patients treated with denosumab: a multicenter case series","volume":"46","author":"Aljohani","year":"2018","journal-title":"J. Craniomaxillofac. Surg."},{"issue":"12","key":"10.1016\/j.bone.2019.115141_bb0165","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1248\/bpb.b15-00385","article-title":"Incidence and risk factors of osteonecrosis of the jaw in advanced cancer patients after treatment with zoledronic acid or denosumab: a retrospective cohort study","volume":"38","author":"Kajizono","year":"2015","journal-title":"Biol. Pharm. Bull."},{"issue":"4","key":"10.1016\/j.bone.2019.115141_bb0170","first-page":"e431","article-title":"Osteonecrosis of the jaw induced by receptor activator of nuclear factor-kappa B ligand (Denosumab) - review","volume":"21","author":"de Oliveira","year":"2016","journal-title":"Med. Oral Patol. Oral Cir. Bucal."},{"key":"10.1016\/j.bone.2019.115141_bb0175","doi-asserted-by":"crossref","unstructured":"H. Abel Mahedi Mohamed, C.E.N. Nielsen, M. Schiodt, Medication related osteonecrosis of the jaws associated with targeted therapy as monotherapy and in combination with antiresorptives. A report of 7 cases from the Copenhagen Cohort, Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 125(2) (2018) 157\u2013163.","DOI":"10.1016\/j.oooo.2017.10.010"},{"issue":"5","key":"10.1016\/j.bone.2019.115141_bb0180","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bone.2019.115141_bb0185","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bone.2014.07.027","article-title":"Spontaneous osteonecrosis of the jaws in the maxilla of mice on antiresorptive treatment: a novel ONJ mouse model","volume":"68","author":"de Molon","year":"2014","journal-title":"Bone"},{"issue":"4","key":"10.1016\/j.bone.2019.115141_bb0190","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/jbmr.2097","article-title":"RANKL inhibitors induce osteonecrosis of the jaw in mice with periapical disease","volume":"29","author":"Aghaloo","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2019.115141_bb0195","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1752-1947-2-47","article-title":"Periodontal disease in a patient receiving Bevacizumab: a case report","volume":"2","author":"Gujral","year":"2008","journal-title":"J. Med. Case Rep."},{"issue":"6","key":"10.1016\/j.bone.2019.115141_bb0200","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1007\/s10147-012-0478-5","article-title":"A retrospective analysis of periodontitis during bevacizumab treatment in metastatic colorectal cancer patients","volume":"18","author":"Ogawa","year":"2013","journal-title":"Int. J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bone.2019.115141_bb0205","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.joms.2012.03.022","article-title":"Unusual bevacizumab-related complication of an oral infection","volume":"71","author":"Magremanne","year":"2013","journal-title":"J. Oral Maxillofac. Surg."},{"issue":"7","key":"10.1016\/j.bone.2019.115141_bb0210","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1038\/bjc.2013.516","article-title":"Buccodental side effects of sunitinib in patients with metastatic renal cell carcinoma","volume":"109","author":"Gilabert","year":"2013","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.bone.2019.115141_bb0215","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.tripleo.2010.04.049","article-title":"Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: presentation of three cases","volume":"110","author":"Hoefert","year":"2010","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"issue":"7","key":"10.1016\/j.bone.2019.115141_bb0220","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/odi.12051","article-title":"Periodontal inflammation in renal transplant recipients receiving everolimus or tacrolimus - preliminary results","volume":"19","author":"Pereira-Lopes","year":"2013","journal-title":"Oral Dis."},{"issue":"4","key":"10.1016\/j.bone.2019.115141_bb0225","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10006-012-0379-9","article-title":"Osteonecrosis of the mandible due to anti-angiogenic agent, bevacizumab","volume":"17","author":"Pakosch","year":"2013","journal-title":"Oral Maxillofac Surg"},{"issue":"5","key":"10.1016\/j.bone.2019.115141_bb0230","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00774-017-0872-1","article-title":"Effect of anti-angiogenesis induced by chemotherapeutic monotherapy, chemotherapeutic\/bisphosphonate combination therapy and anti-VEGFA mAb therapy on tooth extraction socket healing in mice","volume":"36","author":"Akita","year":"2018","journal-title":"J. Bone Miner. Metab."},{"issue":"3","key":"10.1016\/j.bone.2019.115141_bb0235","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1600-0765.1981.tb00976.x","article-title":"The progress of the periodontal syndrome in the rice rat. I. Morphometric and autoradiographic studies","volume":"16","author":"Gotcher","year":"1981","journal-title":"J. Periodontal Res."},{"issue":"6","key":"10.1016\/j.bone.2019.115141_bb0240","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/0030-4220(56)90319-X","article-title":"Periodontal disease in the rice rat. I. Anatomic and histopathologic findings","volume":"9","author":"Gupta","year":"1956","journal-title":"Oral Surg. Oral Med Oral Pathol"},{"issue":"5","key":"10.1016\/j.bone.2019.115141_bb0245","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1601-0825.2011.01893.x","article-title":"Enhanced alveolar bone loss in a model of non-invasive periodontitis in rice rats","volume":"18","author":"Aguirre","year":"2012","journal-title":"Oral Dis."},{"key":"10.1016\/j.bone.2019.115141_bb0250","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.bone.2017.12.025","article-title":"Zoledronic acid increases the prevalence of medication-related osteonecrosis of the jaw in a dose dependent manner in rice rats (Oryzomys palustris) with localized periodontitis","volume":"108","author":"Messer","year":"2018","journal-title":"Bone"},{"issue":"4","key":"10.1016\/j.bone.2019.115141_bb0255","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/odi.13052","article-title":"Zoledronate treatment duration is linked to bisphosphonate-related ONJ prevalence in rice rats with generalized periodontitis","volume":"25","author":"Messer","year":"2019","journal-title":"Oral Dis"},{"issue":"4","key":"10.1016\/j.bone.2019.115141_bb0260","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1600-0765.1981.tb00995.x","article-title":"The progress of the periodontal syndrome in the rice rat. II. The effects of a diphosphonate on the periodontium","volume":"16","author":"Gotcher","year":"1981","journal-title":"J. Periodontal Res."},{"issue":"6","key":"10.1016\/j.bone.2019.115141_bb0265","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.mehy.2010.01.013","article-title":"Drug-induced gingival hyperplasia and scaffolds: they may be valuable for horizontal food impaction","volume":"74","author":"Du","year":"2010","journal-title":"Med. Hypotheses"},{"issue":"34","key":"10.1016\/j.bone.2019.115141_bb0270","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1046\/j.0906-6713.2003.003429.x","article-title":"Detection of localized tooth-related factors that predispose to periodontal infections","volume":"2000","author":"Matthews","year":"2004","journal-title":"Periodontol"},{"issue":"15","key":"10.1016\/j.bone.2019.115141_bb0275","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1158\/1078-0432.CCR-09-3100","article-title":"Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy","volume":"16","author":"Bagri","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.bone.2019.115141_bb0280","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/path.4053","article-title":"Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models","volume":"227","author":"Singh","year":"2012","journal-title":"J. Pathol."},{"issue":"4","key":"10.1016\/j.bone.2019.115141_bb0285","doi-asserted-by":"crossref","first-page":"F773","DOI":"10.1152\/ajprenal.00058.2011","article-title":"Anti-VEGF antibody treatment accelerates polycystic kidney disease","volume":"301","author":"Raina","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"issue":"4","key":"10.1016\/j.bone.2019.115141_bb0290","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/bjc.2012.322","article-title":"Improved efficacy of a novel anti-angiogenic drug combination (TL-118) against colorectal-cancer liver metastases; MRI monitoring in mice","volume":"107","author":"Edrei","year":"2012","journal-title":"Br. J. Cancer"},{"issue":"14","key":"10.1016\/j.bone.2019.115141_bb0295","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1182\/blood-2016-08-736314","article-title":"Initiation of acute graft-versus-host disease by angiogenesis","volume":"129","author":"Riesner","year":"2017","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bone.2019.115141_bb0300","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1093\/neuonc\/now112","article-title":"Limited role for transforming growth factor-beta pathway activation-mediated escape from VEGF inhibition in murine glioma models","volume":"18","author":"Mangani","year":"2016","journal-title":"Neuro-Oncology"},{"issue":"2","key":"10.1016\/j.bone.2019.115141_bb0305","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1074\/jbc.M508199200","article-title":"Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF","volume":"281","author":"Liang","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.bone.2019.115141_bb0310","doi-asserted-by":"crossref","first-page":"40","DOI":"10.30802\/AALAS-JAALAS-18-000032","article-title":"Comparison of isoflurane, ketamine-dexmedetomidine, and ketamine-xylazine for general anesthesia during oral procedures in rice rats (Oryzomys palustris)","volume":"58","author":"Jiron","year":"2019","journal-title":"J. Am. Assoc. Lab. Anim. Sci."},{"issue":"1","key":"10.1016\/j.bone.2019.115141_bb0315","first-page":"21","article-title":"Definition of bone necrosis by the pathologist","volume":"4","author":"Fondi","year":"2007","journal-title":"Clin. Cases. Miner. Bone Metab"},{"issue":"4","key":"10.1016\/j.bone.2019.115141_bb0320","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.oooo.2014.04.017","article-title":"Bisphosphonate-induced osteonecrosis of the jaws: clinical, imaging, and histopathology findings","volume":"118","author":"Franco-Pretto","year":"2014","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"10.1016\/j.bone.2019.115141_bb0325","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jot.2018.01.003","article-title":"Steroid-associated osteonecrosis animal model in rats","volume":"13","author":"Zheng","year":"2018","journal-title":"J Orthop Translat"},{"issue":"2","key":"10.1016\/j.bone.2019.115141_bb0330","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/jor.20733","article-title":"A mouse model for glucocorticoid-induced osteonecrosis: effect of a steroid holiday","volume":"27","author":"Yang","year":"2009","journal-title":"J. Orthop. Res."},{"issue":"1","key":"10.1016\/j.bone.2019.115141_bb0335","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.bone.2013.05.013","article-title":"Chemotherapeutic and antiresorptive combination therapy suppressed lymphangiogenesis and induced osteonecrosis of the jaw-like lesions in mice","volume":"56","author":"Kuroshima","year":"2013","journal-title":"Bone"},{"issue":"6","key":"10.1016\/j.bone.2019.115141_bb0340","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1158\/1078-0432.CCR-10-1614","article-title":"Effect of zoledronate on oral wound healing in rats","volume":"17","author":"Yamashita","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bone.2019.115141_bb0345","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.archoralbio.2016.10.018","article-title":"Age-related periodontitis and alveolar bone loss in rice rats","volume":"73","author":"Aguirre","year":"2016","journal-title":"Arch. Oral Biol."},{"issue":"6","key":"10.1016\/j.bone.2019.115141_bb0350","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1359\/jbmr.070313","article-title":"Effects of basic fibroblast growth factor and a prostaglandin E2 receptor subtype 4 agonist on osteoblastogenesis and adipogenesis in aged ovariectomized rats","volume":"22","author":"Aguirre","year":"2007","journal-title":"J. Bone Miner. Res."},{"issue":"26","key":"10.1016\/j.bone.2019.115141_bb0355","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.bone.2019.115141_bb0360","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/jcb.23423","article-title":"Paclitaxel inhibits osteoclast formation and bone resorption via influencing mitotic cell cycle arrest and RANKL-induced activation of NF-kappaB and ERK","volume":"113","author":"Ang","year":"2012","journal-title":"J. Cell. Biochem."},{"issue":"1","key":"10.1016\/j.bone.2019.115141_bb0365","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s00774-008-0013-y","article-title":"Docetaxel inhibits bone resorption through suppression of osteoclast formation and function in different manners","volume":"27","author":"Takahashi","year":"2009","journal-title":"J. Bone Miner. Metab."},{"issue":"5","key":"10.1016\/j.bone.2019.115141_bb0370","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2165\/00002018-200831050-00001","article-title":"Chemotherapy-associated osteonecrosis in cancer patients with solid tumours: a systematic review","volume":"31","author":"Shim","year":"2008","journal-title":"Drug Saf."},{"issue":"7","key":"10.1016\/j.bone.2019.115141_bb0375","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.joms.2011.08.011","article-title":"Osteonecrosis of the maxilla associated with cancer chemotherapy in patients wearing dentures","volume":"70","author":"Infante-Cossio","year":"2012","journal-title":"J. Oral Maxillofac. Surg."},{"issue":"2","key":"10.1016\/j.bone.2019.115141_bb0380","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2174\/156652411794859223","article-title":"Pathobiology and prevention of cancer chemotherapy-induced bone growth arrest, bone loss, and osteonecrosis","volume":"11","author":"Fan","year":"2011","journal-title":"Curr. Mol. Med."},{"issue":"1","key":"10.1016\/j.bone.2019.115141_bb0385","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000488102","article-title":"Avascular necrosis of bone following chemotherapy in cancer patients with coagulopathy: report of two cases","volume":"11","author":"Hsu","year":"2018","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.bone.2019.115141_bb0390","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1146\/annurev-physiol-022516-034339","article-title":"Macrophage polarization","volume":"79","author":"Murray","year":"2017","journal-title":"Annu. Rev. Physiol."},{"issue":"9","key":"10.1016\/j.bone.2019.115141_bb0395","doi-asserted-by":"crossref","first-page":"6425","DOI":"10.1002\/jcp.26429","article-title":"Macrophage plasticity, polarization, and function in health and disease","volume":"233","author":"Shapouri-Moghaddam","year":"2018","journal-title":"J. Cell. Physiol."},{"issue":"4","key":"10.1016\/j.bone.2019.115141_bb0400","doi-asserted-by":"crossref","first-page":"5208","DOI":"10.1096\/fj.201801791RR","article-title":"Zoledronic acid promotes TLR-4-mediated M1 macrophage polarization in bisphosphonate-related osteonecrosis of the jaw","volume":"33","author":"Zhu","year":"2019","journal-title":"FASEB J."},{"key":"10.1016\/j.bone.2019.115141_bb0405","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s41232-018-0074-9","article-title":"Zoledronic acid exacerbates inflammation through M1 macrophage polarization","volume":"38","author":"Kaneko","year":"2018","journal-title":"Inflamm Regen"},{"issue":"12","key":"10.1016\/j.bone.2019.115141_bb0410","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1158\/1078-0432.CCR-13-0042","article-title":"IL-17-mediated M1\/M2 macrophage alteration contributes to pathogenesis of bisphosphonate-related osteonecrosis of the jaws","volume":"19","author":"Zhang","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.bone.2019.115141_bb0415","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/SAP.0b013e3181828141","article-title":"A review on bevacizumab and surgical wound healing: an important warning to all surgeons","volume":"62","author":"Gordon","year":"2009","journal-title":"Ann. Plast. Surg."},{"issue":"4","key":"10.1016\/j.bone.2019.115141_bb0420","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/iwj.13139","article-title":"Impaired wound healing secondary to bevacizumab","volume":"16","author":"Ahn","year":"2019","journal-title":"Int. Wound J."},{"issue":"1","key":"10.1016\/j.bone.2019.115141_bb0425","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0191040","article-title":"VEGF may contribute to macrophage recruitment and M2 polarization in the decidua","volume":"13","author":"Wheeler","year":"2018","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.bone.2019.115141_bb0430","first-page":"4743","article-title":"Wound complications after bevacizumab treatment in patients operated on for ovarian cancer","volume":"30","author":"Koskas","year":"2010","journal-title":"Anticancer Res."},{"issue":"18","key":"10.1016\/j.bone.2019.115141_bb0435","doi-asserted-by":"crossref","first-page":"6616","DOI":"10.1158\/0008-5472.CAN-04-0401","article-title":"Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies","volume":"64","author":"Bocci","year":"2004","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.bone.2019.115141_bb0440","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","article-title":"A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer","volume":"349","author":"Yang","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"35","key":"10.1016\/j.bone.2019.115141_bb0445","doi-asserted-by":"crossref","first-page":"57197","DOI":"10.18632\/oncotarget.11084","article-title":"The VEGF rise in blood of bevacizumab patients is not based on tumor escape but a host-blockade of VEGF clearance","volume":"7","author":"Alidzanovic","year":"2016","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.bone.2019.115141_bb0450","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/bjc.2012.342","article-title":"Neoadjuvant bevacizumab persistently inactivates VEGF at the time of surgery despite preoperative cessation","volume":"107","author":"Starlinger","year":"2012","journal-title":"Br. J. Cancer"},{"issue":"13","key":"10.1016\/j.bone.2019.115141_bb0455","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1200\/JCO.2006.10.3051","article-title":"Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity","volume":"25","author":"Loupakis","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"31","key":"10.1016\/j.bone.2019.115141_bb0460","doi-asserted-by":"crossref","first-page":"8136","DOI":"10.1200\/JCO.2005.02.5635","article-title":"Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients","volume":"23","author":"Willett","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.bone.2019.115141_bb0465","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1038\/sj.gt.3302772","article-title":"Increased VEGF levels induced by anti-VEGF treatment are independent of tumor burden in colorectal carcinomas in mice","volume":"13","author":"Schmitz","year":"2006","journal-title":"Gene Ther."},{"key":"10.1016\/j.bone.2019.115141_bb0470","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1479-5876-5-32","article-title":"Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins","volume":"5","author":"Deprimo","year":"2007","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.bone.2019.115141_bb0475","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.joms.2016.07.019","article-title":"Osteonecrosis of the jaw in the absence of antiresorptive or antiangiogenic exposure: a series of 6 cases","volume":"75","author":"Aghaloo","year":"2017","journal-title":"J. Oral Maxillofac. Surg."},{"issue":"6","key":"10.1016\/j.bone.2019.115141_bb0480","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/9467","article-title":"VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation","volume":"5","author":"Gerber","year":"1999","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.bone.2019.115141_bb0485","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1002\/ijc.28833","article-title":"Anti-VEGF antibody enhances the antitumor effect of CD40","volume":"135","author":"Selvaraj","year":"2014","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.bone.2019.115141_bb0490","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0022-3565(24)37962-5","article-title":"Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor","volume":"288","author":"Lin","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328219304351?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328219304351?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:47:24Z","timestamp":1757612844000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328219304351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":98,"alternative-id":["S8756328219304351"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2019.115141","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-vascular endothelial growth factor antibody monotherapy causes destructive advanced periodontitis in rice rats (Oryzomys palustris)","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2019.115141","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115141"}}